Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials

Fig. 3

Efficacy comparison of maintenance therapy between Pem + B and B. a. mPFS; b. mOS; c. ORR. Abbreviations: Pem + B, pemetrexed and bevacizumab; B, bevacizumab; mPFS, median progression-free survival; mOS, median overall survival; ORR, objective response rates

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us